Incisive Genetics is developing a delivery platform for genetic therapies. This disruptive and transformational lipid nanoparticle (LNP) based delivery platform generated using IG’s proprietary technology enables a one-step encapsulation of key active CRISPR components in one package. The goal of our initial business operations is to finish key studies that will lead to partnerships with pharma partners and expand our patent portfolio.